Detail info about the product:
Packing: Aerosol 20ml
I.R.S. 19® (Solvay, Brussels, Belgium) is a nasal spray suspension of lysates of 19 respiratory bacteria.
Indication : Preventing exacerbations of chronic diseases upper respiratory tract and bronchial adults and children from 3 months.
Treatment of acute and chronic bacterial upper respiratory infections and bronchial adults and children from 3 months (rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis).
Restoring local immunity after an influenza and other viral infections.
Preparations for the planned rapid intervention in the OECD and in the aftercare period.
Increased susceptibility to the drug or its components in history.
IRS ® 19 should not assign patients with autoimmune diseases.
Application of pregnancy and breast-feeding : It is not recommended during pregnancy and breastfeeding (for the potential teratogennogo or toxic effects on the fetus, as well as the possibility of infiltration LS in breast milk are not available).
Side Effects :
Skin reactions : rarely possible hypersensitivity reactions (urticaria, angionevrotichesky swelling), and skin and eritemopodobnye ekzemopodobnye reaction.
For the OECD and the respiratory organs : rarely his asthma and cough.
In rare instances, early treatment can be observed - raising body temperature (> 39 ° C), nausea, vomiting, abdominal pain, diarrhoea, rhinopharyngitis, sinusitis, laryngitis, bronchitis.
For those receiving the drug, described isolated occurrence trombotsitopenicheskoy purpury fingers and erythema.
Networking : Cases of negative interactions with other LS unknown.
Cases overdose unknown.
Dosing and Administration :
Intranasal (using a bottle to keep upright).
To prevent adults and children from 3 months of age (2-3 weeks before the expected recovery of disease), and 1 dose of the drug (one dose = 1 briefly pushing the spray gun) in a bow at 2 times a day for 2 weeks.
For the treatment of acute and chronic upper respiratory tract and bronchial : adults and children older than 3 years and 1 dose of the drug in each bow at 2-5 times a day; Children from 3 months to 3 years and 1 dose of the drug in each bow during two times a day (after the release of mucous separated). Treatment prior to the disappearance of the symptoms of the infection.
To restore local immunity post-influenza and other respiratory viral infections : adults and children - one dose of the drug in each bow during two times a day for 2 weeks.
In preparation for the planned rapid intervention and aftercare period : adults and children - one dose of the drug two times a day over 2 weeks (to start a course of treatment is recommended for 1 week before the planned intervention).
Early treatment can be such reaction as sneezing and increased emissions from the nose. Typically, they are of short duration. If these reactions will be a heavy, should be reduced concentrations of drug or repealed. In developing the clinical symptoms of the bacterial infection should be considered for treatment with antibiotics in the face of continued therapy IRS 19.
The use of IRS 19 has no effect on psychomotor functions associated with driving a car or office machines and mechanisms.
Special instructions :
If you leave preparation for a long time without use, a drop of liquid can evaporate and the resulting crystals clog outlet nozzles. This phenomenon occurs most often when the nozzle removed and put into the packaging end of the top-down next to a bottle, without promyv not prosushiv it. When hardening nozzles make several clicks a row that liquid can be caused by excess pressure. If that does not help, head lowered for a few minutes in warm water.
In appointing drugs on the basis of bacterial lizatov immune to patients with bronchial asthma may cause asthma attacks. In this case, discontinue treatment or take drugs of this class in the future.